N/A Completed N=20 Prevention

The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte Donors

Source: ClinicalTrials.gov NCT00867659 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2013

Primary outcomePrimary: Volume of Ascites in the Abdomen is Indicative of the Severity of OHSS — 10 cc (volume of ascites)

Summary

This pilot study aims to address whether the prophylactic use of Cetrorelix Acetate after a long gonadotropin-releasing hormone (GnRH) agonist protocol post-hCG (human chorionic gonadotropin) administration can significantly reduce the incidence of OHSS in oocyte donors.

Outcome Measures

Outcome	Result	p-value
PRIMARY Volume of Ascites in the Abdomen is Indicative of the Severity of OHSS	10	—
PRIMARY Ovarian Volumes as a Predictor of OHSS Severity	25	—

Eligibility Criteria

Inclusion Criteria

Prospective donors with BMIs between 19 and 28,
Those with normal FSH levels and good antral follicle counts between 19-28 years of age, AND
Donors would have passed all the required testing as mandated by VCRM and the FDA.

Exclusion Criteria

Oocyte donors exceeding a BMI of > 28,
Those with any communicable diseases,
Those with low antral follicle counts and small ovarian volumes,
Those with elevated FSH levels,
Those with positive sickle cell screen or cystic fibrosis screening,
Smokers, OR
Donors who are unable or unwilling to follow the research protocols.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00867659). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.